SkinHealth Systems Inc. (SKIN) stock
Close on Nov 17, 2026Market cap $1.81BP/E –Yield –
Earnings
SkinHealth Systems's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of SkinHealth Systems's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $69.20M | -2.1% | -$0.14 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $72.10M | -7.8% | -$0.02 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $64.90M | -6.8% | -$0.05 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026after the close | $82.40M | -1.3% | -$0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $70.70M | -10.3% | -$0.09 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $78.20M | -13.7% | $0.03 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $69.60M | -14.5% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 12, 2025after the close | $83.50M | -13.7% | -$0.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $78.80M | -19.1% | -$0.15 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $90.60M | -22.9% | -$0.10 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $81.40M | -5.7% | -$0.10 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024after the close | $96.80M | -1.3% | -$0.07 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023after the close | $97.40M | +9.7% | -$0.56 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023before the open | $117.50M | +13.5% | $0.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023before the open | $86.30M | +14.5% | -$0.17 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | $98.10M | +25.9% | $0.03 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $88.80M | +30.4% | -$0.03 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | $103.50M | – | -$0.05 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $75.40M | – | -$0.13 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 22, 2022after the close | $77.90M | – | -$0.12 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $68.10M | – | -$1.63 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
SkinHealth Systems's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net salesGAAP | FY2026 | $281.00M – $287.00M | – | New | Nov 5, 2026 |
| Net sales | FY2026 | $280.00M – $290.00M | $285.00M – $305.00M | Lowered | Aug 6, 2026 |
| Net salesGAAP | FY2026 | $280.00M – $295.00M | – | New | May 7, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $48.00M – $50.00M | – | New | Nov 5, 2026 |
| Adjusted EBITDA (1)non-GAAP | FY2026 | $39.00M – $46.00M | $35.00M – $45.00M | Raised | Aug 6, 2026 |
Guidance vs results
The last range SkinHealth Systems gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $65.00M – $70.00M | $69.20M | Within range |
| Q2 FY2026 | Revenue | $72.00M – $77.00M | $72.10M | Within range |
| Q1 FY2026 | Revenue | $63.00M – $68.00M | $64.90M | Within range |
| FY2025 | Revenue | $293.00M – $300.00M | $300.90MΣ4Q | Above range |
| Q3 FY2025 | Revenue | $65.00M – $70.00M | $70.70M | Above range |
| Q1 FY2025 | Revenue | $61.00M – $66.00M | $69.60M | Above range |
| Q3 FY2024 | Revenue | $70.00M – $80.00M | $78.80M | Within range |
| Q2 FY2024 | Revenue | $96.00M – $102.00M | $90.60M | Below range |
| Q1 FY2024 | Revenue | $77.00M – $83.00M | $81.40M | Within range |
Guidance history
Every forecast SkinHealth Systems put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted EBITDA | FY2026 | $48.00M – $50.00M | New |
| Nov 5, 2026 | Net sales | FY2026 | $281.00M – $287.00M | New |
| Aug 6, 2026 | Adjusted EBITDA (1) | FY2026 | $39.00M – $46.00M | Raised |
| Aug 6, 2026 | Adjusted EBITDA (1) | Q3 FY2026 | $5.00M – $7.00M | New |
| Aug 6, 2026 | Net sales | FY2026 | $280.00M – $290.00M | Lowered |
| Aug 6, 2026 | Net sales | Q3 FY2026 | $65.00M – $70.00M | New |
| May 7, 2026 | Adjusted EBITDA | FY2026 | $35.00M – $45.00M | Reaffirmed |
| May 7, 2026 | Adjusted EBITDA | Q2 FY2026 | $11.00M – $13.00M | New |
| May 7, 2026 | Net sales | FY2026 | $280.00M – $295.00M | New |
| May 7, 2026 | Net sales | Q2 FY2026 | $72.00M – $77.00M | New |
| Mar 12, 2026 | Adjusted EBITDA | FY2026 | $35.00M – $45.00M | New |
| Mar 12, 2026 | Adjusted EBITDA | Q1 FY2026 | $3.50M – $5.50M | New |
| Mar 12, 2026 | Net sales | FY2026 | $285.00M – $305.00M | New |
| Mar 12, 2026 | Net sales | Q1 FY2026 | $63.00M – $68.00M | New |
| Nov 6, 2025 | Adjusted EBITDA | FY2025 | $37.00M – $39.00M | New |
| Nov 6, 2025 | Net sales | FY2025 | $293.00M – $300.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | Q3 FY2025 | $2.00M – $4.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $27.00M – $35.00M | Raised |
| Aug 7, 2025 | Net sales | Q3 FY2025 | $65.00M – $70.00M | New |
| Aug 7, 2025 | Net sales | FY2025 | $285.00M – $300.00M | Raised |
| Mar 12, 2025 | Adjusted EBITDA | Q1 FY2025 | -$6.00M – -$4.00M | New |
| Mar 12, 2025 | Adjusted EBITDA | FY2025 | $10.00M – $25.00M | New |
| Mar 12, 2025 | Net sales | Q1 FY2025 | $61.00M – $66.00M | New |
| Mar 12, 2025 | Net sales | FY2025 | $270.00M – $300.00M | Lowered |
| Nov 12, 2024 | Adjusted EBITDA | FY2024 | -$2.00M – $4.00M | Raised |
| Nov 12, 2024 | Net sales | FY2024 | $322.00M – $332.00M | New |
| Aug 8, 2024 | Adjusted EBITDA | Q3 FY2024 | -$6.00M – -$1.00M | New |
| Aug 8, 2024 | Adjusted EBITDA | FY2024 | -$10.00M – $0 | Lowered |
| Aug 8, 2024 | Net sales | Q3 FY2024 | $70.00M – $80.00M | New |
| Aug 8, 2024 | Net sales | FY2024 | $325.00M – $345.00M | New |
| May 9, 2024 | Adjusted EBITDA | Q2 FY2024 | $4.00M – $7.00M | New |
| May 9, 2024 | Adjusted EBITDA | FY2024 | $40.00M | Reaffirmed |
| May 9, 2024 | Net sales | Q2 FY2024 | $96.00M – $102.00M | New |
| Mar 12, 2024 | Adjusted EBITDA | Q1 FY2024 | -$9.00M – -$6.00M | New |
| Mar 12, 2024 | Adjusted EBITDA | FY2024 | $40.00M | New |
| Mar 12, 2024 | Net sales | Q1 FY2024 | $77.00M – $83.00M | New |
| Nov 13, 2023 | adjusted EBITDA margin | FY2023 | 5% – 6% | Lowered |
| Nov 13, 2023 | net sales | FY2023 | $385.00M – $400.00M | Lowered |
| Aug 9, 2023 | Adjusted EBITDA margin | FY2023 | 18% – 19% | Lowered |
| Aug 9, 2023 | Adjusted EBITDA margin | FY2025 | 25% – 30% | Reaffirmed |
| Aug 9, 2023 | Net sales | FY2023 | $460.00M – $480.00M | Reaffirmed |
| Aug 9, 2023 | Net sales | FY2025 | $600.00M – $700.00M | Reaffirmed |
| May 10, 2023 | Adjusted EBITDA margin | FY2023 | 18% – 20% | Reaffirmed |
| May 10, 2023 | Adjusted EBITDA margin | FY2025 | 25% – 30% | Reaffirmed |
| May 10, 2023 | Net sales | FY2023 | $460.00M – $480.00M | New |
| May 10, 2023 | Net sales | FY2025 | $600.00M – $700.00M | New |
| Feb 28, 2023 | adjusted EBITDA margin | FY2023 | 18% – 20% | New |
| Feb 28, 2023 | adjusted EBITDA margin | FY2025 | 25% – 30% | New |
| Feb 28, 2023 | net sales | FY2023 | $450.00M – $470.00M | New |
| Feb 28, 2023 | net sales | FY2025 | $600.00M – $700.00M | New |
| Nov 8, 2022 | capital expenditures | FY2022 | $20.00M | Reaffirmed |
| Nov 8, 2022 | adjusted EBITDA | FY2022 | $45.00M – $50.00M | Lowered |
| Nov 8, 2022 | net sales | FY2022 | $360.00M – $365.00M | Raised |
| Aug 9, 2022 | capital expenditures | FY2022 | $20.00M | Reaffirmed |
| Aug 9, 2022 | adjusted EBITDA | FY2022 | $50.00M | Reaffirmed |
| Aug 9, 2022 | net sales | FY2022 | $340.00M – $350.00M | Raised |
| May 10, 2022 | capital expenditures | FY2022 | $20.00M | New |
| May 10, 2022 | adjusted EBITDA | FY2022 | $50.00M | Reaffirmed |
| May 10, 2022 | net sales | FY2022 | $330.00M – $340.00M | New |
| Feb 22, 2022 | capital expenditures | FY2022 | $20.00M | New |
| Feb 22, 2022 | adjusted EBITDA | FY2022 | $50.00M | New |
| Feb 22, 2022 | net sales | FY2022 | $320.00M – $330.00M | New |
| Nov 9, 2021 | capital expenditures | FY2021 | $15.00M | New |
| Nov 9, 2021 | Adjusted EBITDA | FY2021 | $30.00M | New |
| Nov 9, 2021 | Net sales | FY2021 | $245.00M – $255.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases SkinHealth Systems filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Update
- Update
- Results
- News
- Results
- Update
- Update
- Results
- Update
- Results
- Results
See a number that looks wrong?